The news Gilead Sciences dropped Monday was so disappointing it irked even the nicest guy in biotech.
Brad Loncar, an investor based in Kansas City whose cancer-focused exchange-traded fund holds Gilead shares, is a Ted Lasso-like font of cheeriness amid bio-Twitter’s angry froth. Yet even he was upset about the way Gilead and its CEO, Dan O’Day, released information about a key study of its breast cancer drug, Trodelvy — without any specific data. In 2020, Gilead had paid $21 billion for the drug and its maker, Immunomedics.
“I like him personally and respect his career experience, but how does Dan O’Day keep his job as $GILD CEO with this deal record?” Loncar tweeted. “And probably half the board too.”
About the Author Reprints
Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us on Twitter, Facebook, LinkedIn, and Threads. Let's stay connected!
To submit a correction request, please visit our Contact Us page.